Cookies on the BTG website

We use cookies to ensure that we give you the best experience on our website.

If you continue without changing your settings, we'll assume that you are happy to receive all cookies on the BTG website.

Find out more
Continue

Media

Utilities
Print
Email
Email to a friend
Email to a friend

* Required

BTG plc: Varisolve® NDA submitted to the FDA

London, UK, 4 February 2013: BTG plc (LSE: BTG), the specialist healthcare company, today announces that a New Drug Application (NDA) seeking approval of Varisolve® (polidocanol endovenous microfoam (PEM)) as a comprehensive treatment for varicose veins has been submitted to the US Food & Drug Administration (FDA). BTG expects to hear within Q2 2013 (calendar year) as per the usual FDA timelines whether after initial review the submission has been accepted for full review.

For further information contact:

BTG
Andy Burrows, Director of Investor Relations
+44 (0)20 7575 1741; Mobile: +44 (0)7990 530605

Rolf Soderstrom, Chief Financial Officer
+44 (0)20 7575 0000

FTI Consulting
Ben Atwell
+44 (0)20 7831 3113

About BTG
BTG is an international specialist healthcare company that is developing and commercialising products targeting critical care, cancer and other disorders. The company has diversified revenues from sales of its own marketed products and from royalties on partnered products, and is seeking to acquire new programmes and products to develop and market to specialist physicians.